Spenolimycin
is a new spectinomycin-type antibiotic isolated from Streptomyces gilvospiralis sp. nov.
In vitro, it was active against a wide variety of aerobic Gram-positive and Gramnegative bacteria and Neisseria gonorrhoeae.
It was two to four-fold more active against N. gonorrhoeae than spectinomycin. Spenolimycin was effective in the standard mouse protection test against Escherichia coli, Klebsiella pneumoniae and Streptococcus pneumoniae.
is a new spectinomycin-like antibiotic isolated from Streptomyces gilvospiralis sp.
nov. Its discovery, the taxonomy of the producing culture, fermentation, isolation and structure determination have been described in the two preceding papers1,2). The microbiological profile of this antibiotic is described in this paper. Spectinomycin was used as the reference compound for all studies. 
Test Bacteria
The aerobic Gram-positive and Gram-negative bacteria including Neisseria gonorrhoeae were from the Abbott culture collection. These organisms are maintained at -70°C or lyophilized. N. gonorrhoeae strains 84M and F28 were obtained from the Center for Disease Control, Atlanta, Georgia, and are spectinomycin-sensitive and spectinomycin-resistant strains, respectively.
In Vitro Potency Determinations The minimal inhibitory concentrations (MICs) of spenolimycin were determined using the agar dilution procedure,' on brain heart infusion agar. N. gonorrhoeae was grown in a 7 % CO, atmosphere on GC agar base (Difco) supplemented with 1 ° (v/v) IsoVitalex and 1 % (w/v) hemoglobin.
Mouse Protection Tests CF-1 female mice were infected by injecting 100 LD50 doses of Escherichia coli Juhl, 10 LD50 doses of Klebsiella pneumoniae 4508 or 1,000 LD50 doses of Streptococcus pneumoniae 6303 intraperitoneally. Hog gastric mucin (5 w/v) was mixed with the E. coli and K. pneumoniae prior to intraperitoneal injection. Groups of ten mice infected in this manner were treated with three different graded doses of spenolimycin or spectinomycin at 1 and 5 hours post-infection. The median effective dose (ED50) was calculated on the basis of cumulative mortalities on the sixth day by a trimmed version of the Logit method4).
Results and Discussion
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